Oral suspension sulfonylurea safe, effective in children with neonatal diabetes

Children with neonatal diabetes switched from glibenclamide tablets to an oral suspension sulfonylurea therapy for 4 months experienced only mild adverse effects and no changes in HbA1c or incidence of hyperglycemia or hypoglycemia, according to findings from a phase 2 study published in Pediatric Diabetes.

Source: Oral suspension sulfonylurea safe, effective in children with neonatal diabetes